ASHLEY MELUGIN: Open Payments
NPI 1881094902 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,696 in 176 payments from 12 companies in 2025. Trend: 2023 $2,235 · 2024 $2,191 · 2025 $2,696
Food & beverage: $2,696
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $493 |
| Neurocrine BioSciences, Inc. | 31 | $432 |
| Otsuka America Pharmaceutical, Inc. | 28 | $347 |
| Janssen Pharmaceuticals, Inc | 22 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $296 |
| Vanda Pharmaceuticals Inc. | 13 | $285 |
| Alkermes, Inc. | 14 | $172 |
| ABBVIE INC. | 10 | $144 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
Products named: INGREZZA, UZEDY, CAPLYTA, REXULTI, INVEGA SUSTENNA, FANAPT, AUSTEDO XR, ARISTADA.
Industry payments across KS — which companies pay providers there.
